Lung Cancer

Rybrevant plus Lazcluze, compared with Tagrisso, showed a trend towards favorable overall survival in EGFR-positive advanced non-small cell lung cancer.

With pivotal trial results and an approval from the FDA, the landscape is changing for patients with small cell lung cancer.

The recent FDA approval of Lazcluze plus Rybrevant for EGFR-mutant non-small cell lung cancer is a “big deal” for patients, an oncologist said.

The antibody-drug conjugate GSK’227 is intended to treat patients with extensive-stage small cell lung cancer.

As a cancer survivor, I’ve found that support from friends and family makes a difference, so here are three ways they can help during survivorship.

Fatigue is a common side effect that may linger for years following cancer treatment. Experts and survivors talk about ways to help find a balance between life and fatigue.

In August 2024, the FDA approved six new cancer treatments, including some that haven’t previously been approved.

The Food and Drug Administration approved frontline Lazcluze plus Rybrevant for locally advanced or metastatic non-small cell lung cancer with an EGFR exon 19 deletions or exon 21 L858R substitution mutations.

From Susan Wojcicki and Rachael Lillis dying of cancer to the President Biden announcing that Cancer Moonshot initiative received $150 million, here’s what’s happening in the oncology space.

Patients with NSCLC who are overweight or obese should discuss chemotherapy versus immunotherapy for frontline treatment, research showed.

Imfinzi has been approved as a presurgical treatment with platinum-based chemotherapy and postsurgical treatment alone in surgically removable NSCLC.

Patients with NSCLC taking five or more medications tended to have worse survival, highlighting the need for medication management, research showed.

Olomorasib plus Keytruda was proven to be safe and well tolerated for patients with KRAS G12C-mutant non-small cell lung cancer.

One expert explains how a break in TKI treatment could alleviate some toxicities, such as rash, for patients with non-small cell lung cancer.

From Patti Yasutake’s death from cancer to Olympic water polo player’s husband’s rare cancer diagnosis, here’s what’s happening in the oncology space this week.

The cancer vaccine, mRNA-4157, garnered immune responses of 30 weeks among some patients with melanoma and lung cancer, study results showed.

Patients with unresectable stage 3 non-small cell lung cancer treated with Tecentriq before and following chemoradiation may derive a survival benefit.

Certain patients with non-small cell lung cancer who are treatment-naive may benefit from receiving a biopsy regarding treatment decision-making.

Among patients with EGFR-mutated, advanced NSCLC, frontline treatment with Rybrevant plus Leclaza significantly prolonged progression-free survival.

I’ve been involved in the cancer community — in one way or another — since the 1990s, when my mother was facing breast cancer.

Treatment responses to Xalkori were not affected by PD-L1 expression in patients with advanced non-small cell lung cancer and ROS1 rearrangements.

A novel antibody-drug conjugate received an investigational new drug application for patients with gynecologic and lung cancers.

23andMe and 20 lung cancer advocacy organizations are working to improve lung cancer detection, risk reduction and care.

Sequencing the novel drug, THIO, with Libtayo tended to be tolerable in patients with non-small cell lung cancer, recent research showed.

A friend of mine is strong in her faith and is living well with a stage 4 cancer diagnosis. She is someone I look up to in these matters.

For some patients with early non-small cell lung cancer and lung scarring, stereotactic ablative radiotherapy may be a viable option, research has shown.

During summer 2024, there have been many changes made in the non-small cell lung cancer and small cell lung cancer spaces. Here are four top news stories.

When I started receiving chemotherapy for stage 3B lung cancer, I initially felt hopeless.

I used to think that having lung cancer canceled all of my life's plans, but I realized I shouldn't give it that much power.

Imdelltra has offered a new treatment option for patients with small cell lung cancer that “is not like anything we’ve ever seen before,” an expert said.